Drugs / HC-7366
HC-7366
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07401875 | Mar 2026 → Nov 2027 expected | kidney cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06285890 | May 2024 → Dec 2027 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06234605 | Apr 2024 → Nov 2026 expected | renal cell carcinoma | HiberCell, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05121948 | Feb 2022 → Feb 2024 | bladder transitional cell carcinoma, clear cell renal carcinoma, colorectal cancer, head and neck squamous cell carcinoma +1 | HiberCell, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC-7366 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05121948 ↗ |
| Known as | HC-7366 potassium salt monohydrate | “HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration.” NCT05121948 ↗ |
| Known as | HC-7366-K | “HC-7366 drug product is an immediate release capsule formulation of HC-7366 potassium salt monohydrate (HC-7366-K) in a hard gelatin capsule for oral administration.” NCT05121948 ↗ |
| Action | Activate | “GCN2) kinase activator.” NCT06234605 ↗ |
| Route | Oral | “HC-7366 administered orally once a day” NCT05121948 ↗ |